¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"serotonin hypothesis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 7 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • specific serotonin reuptake inhibitor
    ƯÀ̼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • serotonin
    ¼¼·ÎÅä´Ñ
  • hypothesis
    °¡¼³
  • lattice hypothesis
    °ÝÀÚ°¡¼³
  • null hypothesis
    ¿µ°¡¼³, ±Í¹«°¡¼³
  • unitarian hypothesis
    Ç×üµ¿Àϰ¡¼³
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypothesis
    °¡¼³
  • null hypothesis
    ±Í¹«°¡¼³, ¿µ°¡¼³
  • selective serotonin reabsorption inhibitor
    ¼±Åü¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • serotonin
    ¼¼·ÎÅä´Ñ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • specific serotonin reuptake inhibitor
    ¼±ÅÃÀû¼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • serotonin
    ¼¼·ÎÅä´Ñ
  • blending hypothesis
    À¶ÇÕÀ¯Àü¼³
  • central plasticity hypothesis
    ÁßÃßÀ¯¿¬¼º°¡¼³
  • countercurrent hypothesis
    ¿ª·ù°¡¼³
  • drift hypothesis
    À̵¿°¡¼³
  • dual recognition hypothesis
    Ç׿øÀÌÁßÀÎÁö°¡¼³
  • estrogen window hypothesis
    ¿¡½ºÆ®·Î°Õâ°¡¼³
  • expectation hypothesis
    ¿¹Ãø°¡¼³
  • hypothesis
    °¡¼³
  • hypoxia-selectivity hypothesis
    Àú»ê¼ÒÁõ¼±Åõµ°¡¼³
  • lattice hypothesis
    °ÝÀÚ°¡¼³
  • lipid hypothesis
    ÁöÁú°¡¼³
  • metabolic hypothesis
    ´ë»ç°¡¼³
  • molecular hypothesis
    ºÐÀÚ°¡¼³
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 6 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hydroxytryptamine, 5-hydroxytryptamine (serotonin)
    5-ÇÏÀ̵å·Ï½ÃÆ®¸³Å¸¹Î(¼¼·ÎÅä´Ñ)
  • Glucostatic hypothesis, of appetite regulation
    Ç×´ç±â¼³(ù÷ÓØÐñæò), ½Ä¿åÁ¶Àý(ãÝé¯ðàï½)
  • Lyon s hypothesis
    ¶óÀ̿°¡¼³.
  • Starling s hypothesis
    ½ºÅ¸¾Ë¸µ°¡¼³.
  • hypothesis, lattice
    °ÝÀÚ¼³
  • receptor hypothesis
    ¼ö¿ëü°¡¼³
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hydroxytryptamine, 5-hydroxytryptamine (serotonin)
    5-ÇÏÀ̵å·Ï½ÃÆ®¸³Å¸¹Î(¼¼·ÎÅä´Ñ)
  • selective serotonin reuptake inhibitor(SSRI)
    ¼±ÅÃÀû ¼¼·ÎÅä´Ñ ÀçÈí¼ö¾ïÁ¦Á¦
  • serotonin
    ¼¼·ÎÅä´Ñ.
  • serotonin
    ¼¼·ÎÅä´Ñ(¡­)
  • serotonin syndrome, with MAOIs
    ¼¼·ÎÅä´ÑÁõÈıº(´Ü°¡¾Æ¹Î»êÈ­È¿¼Ò¾ïÁ¦Á¦)
  • serotonin-nonselective reuptake inhibitor
    ºñ¼±ÅÃÀû ¼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • serotonin-nonspecific reuptake inhibito£ò
    ºñƯÁ¤¼º ¼¼·ÎÅä´Ñ ÀçÈí¼ö¾ïÁ¦Á¦
  • specific serotonin reuptake inhibitor(SSRI)
    ¼±ÅÃÀû ¼¼·ÎÅä´Ñ ÀçÈí¼ö¾ïÁ¦Á¦
  • atherosclerosis,monoclonal hypothesis
    ´ÜÀÏŬ·Ð¼º°¡¼³(Ó¤ìé¡­Ê£àã)
  • atherosclerosis,reaction to injury hypothesis
    ¼Õ»ó¿¡ ´ëÇÑ ¹ÝÀÀ±âÀü
  • atomic hypothesis
    ¿øÀÚ°¡¼³(ê«í­Ê£æò).
  • blending hypothesis
    À¶ÇÕÀ¯Àü¼³(¡­ë¶îîæò).
  • countercurrent hypothesis
    ¿ª·ù°¡¼³ (¡­Ê£æò).
  • cyclol hypothesis
    »çÀÌŬ·Ñ ´ÜÀ§°¡¼³(¡­Ó¤êÈÊ£æò).
  • dopamine hypothesis
    µµÆÄ¹Î °¡¼³
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • serotonin hypothesis
    ¼¼·ÎÅä´Ñ¼³(àã)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • serotonin
    ¼¼·ÎÅä´Ñ
  • acetate hypothesis
    ¾Æ¼¼Æ®»ê(ß«) ¼³(àã)
  • adapter hypothesis
    ¾Æ´äÅͼ³(àã)
  • adenylate charge hypothesis
    ¾Æµ¥´Ò»ê(ß«)´ëÀü¼³(Óáï³àã)
  • adenylate control hypothesis
    ¾Æµ¥´Ò»ê(ß«)Á¶Àý¼³(ðàï½àã)
  • Akabori hypothesis
    ¾ÆÄ«º¸¸®¼³(àã)
  • autocrine hypothesis
    ÀÚ°¡ºÐºñ¼³ (í»Ê«ÝÂÝôàã)
  • Belling's hypothesis
    º§¸µ¼³(àã)
  • biochemical coupling hypothesis
    »ýÈ­ÇÐÀû(ßæûùùÊîÜ) ¦ÁöÀ½¼³(àã)
  • biochemical deletion hypothesis
    »ýÈ­ÇÐÀû(ßæûùùÊîÜ)°á½Ç¼³(ÌÀã÷àã)
  • biogenic amine hypothesis
    »ýü(ßæô÷)¾Æ¹Î¼³(àã)
  • bookmark hypothesis
    ¼­Ç¥¼³(ßöøöàã)
  • catabolic deletion hypothesis
    ÀÌÈ­´ë»çÀû °á¼Õ¼³(ì¶ûùÓÛÞóîÜ ÌÀáßàâ)
  • chemical coupling hypothesis
    È­ÇÐ(ûùùÊ) Ä«Çøµ¼³(àã)
  • chemiosmotic coupling hypothesis
    È­ÇлïÅõ(ûùùÊß¶÷â) ¦ÁöÀ½¼³(àã)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 1 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • hypothesis
    °¡¼³
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
H0 null hypothesis
H1 alternative hypothesis
LNH large number hypothesis
TRH tension-reducing hypothesis; thyrotropin-releasing hormone
5-HT 5-Hydroxy-Tryptamine
  = Serotonin
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
(3)H hypothesis that
[(3)H]-5-HT 3)H]-serotonin
5-HT 3)H]serotonin
5-HT 5-hydroxytryptophan , a serotonin
5HT Histamine , serotonin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • serotonin antagonist
    ¼¼·ÎÅä´Ñ ±æÇ×Á¦
  • serotonin neuron
    ¼¼·ÎÅä´Ñ ´º¿ì·±
  • serotonin syndrome
    ¼¼·ÎÅä´Ñ ÁõÈıº
  • thrombotonin µ¿ÀǾî=serotonin.

    thromboxane

    Æ®·Òº¹¼¼ÀÎ
    Æ®·Òº¹»ê A2 ¶Ç´Â Æ®·Òº¹»ê B2ÀÇ µÎ È­ÇÕ¹° Áß ¾î´À Çϳª¸¦ ÁöĪÇÑ´Ù. Æ®·Òº¹»ê ¿¡ÀÌ Åõ´Â Ç÷¼ÒÆÇ ÀÀÁý°ú Ç÷¼ÒÆÇ À¯¸® ¹ÝÀÀÀÇ °­·ÂÇÑ À¯µµ ¹°ÁúÀ̸ç, Ç÷°ü ¼öÃà ÀÛ¿ëÀ» °¡Áö°í ÀÖ´Ù. ±×·¯¹Ç·Î ÀÌ ¹°ÁúÀº ÇÁ·Î½ºÅ¸»çÀÌŬ¸°ÀÇ »ý¸®ÇÐÀû ±æÇ× ¹°ÁúÀÌ´Ù. Æ®·Òº¹»ê A2´Â Ç÷¼ÒÆÇ¿¡¼­ ÇÕ¼ºµÇ¸ç, ¸Å¿ì ºÒ¾ÈÁ¤ÇÏ¿© ºñÈ¿¼Ò¼ºÀ¸·Î °¡¼öºÐÇØµÇ¾î, Æ®·Òº¹»ê B2°¡ µÇ¸ç, Æ®·Òº¹»ê B2´Â ºÒȰ¼ºÀÎ ¹°Áú·Î¼­ ¹Ý°¨±â°¡ ¾à 30ÃÊÀÌ´Ù.
  • altered-self hypothesis
    º¯È­ÇÑ ÀÚ±â Ç׿ø °¡¼³
    T-B Çùµ¿ÀÛ¿ëÀ̳ª Killer T ¼¼Æ÷ÀÇ Ç¥Àû¼¼Æ÷ÀÇ ÀÎ½Ä ±â±¸¿¡ À־ ¸²ÇÁ±¸´Â ¹ÝÀÀÇÏ´Â »ó´ëÀÇ ±¸Á¶·Î¼­ ºñÀÚ±âÀÎ Ç׿ø°ú ÀÚ±âÀÎ MHCÀÇ ¾çÂÊÀ» ÀνÄÇϰí ÀÖ´Ù. ÀÌ °æ¿ì »ý°¢ÇÏ´Â ¹æ½Ä¿¡ µÎ °³ÀÇ ¹æ½ÄÀÌ ÀÖÀ¸¸ç ºñÀÚ±â¿Í ÀڱⰡ ÇϳªÀÇ °ÍÀ¸·Î¼­ ÇÑ Á¾·ùÀÇ ¼ö¿ëü¿¡ ÀÇÇÏ¿© ÀÎ½ÄµÈ´Ù°í »ý°¢ÇÏ´Â °ÍÀÌ º¯È­ÇÑ ÀÚ°¡ Ç׿ø °¡¼³ÀÇ »ý°¢ ¹æ½ÄÀÌ´Ù.
  • convergence-projection hypothesis
    ÆøÁÖ Åõ»ç °¡¼³
  • dual recognition hypothesis
    2Áß Àνļ³
    ¸é¿ª ¼¼Æ÷ »çÀÌÀÇ »óÈ£ ÀÛ¿ë¿¡ À־ÀÇ T ¼¼Æ÷ÀÇ ÀÎ½Ä ±â±¸¿¡ °üÇÑ °¡¼³ÀÇ Çϳª. T ¼¼Æ÷¿¡´Â ÀÚ±âÀÇ MHC ºÐÀÚ¸¦ ÀνÄÇϱâ À§ÇÑ ¼ö¿ëü¿Í ´Ù¸¥ °ÍÀ» ÀνÄÇϱâ À§ÇÑ ¼ö¿ëü°¡ °¢°¢ µ¶¸³ÇÏ¿© Á¸ÀçÇÑ´Ù°í ÇÏ´Â »ý°¢.
  • hypothesis
    °¡¼³
    ¸î °¡ÁöÀÇ Çö»óÀ» ¼³¸íÇÒ ¼ö ÀÖÀ¸¸ç Ãß·ÐÀ̳ª ½ÇÇèÀ» ±âÃÊ·Î ÇÏ¿© °¡Á¤µÈ ÃßÃø.
  • Starling's hypothesis
    ½ºÅ»¸µÀÇ °¡¼³
  • unitarian hypothesis
    Ç×ü µ¿Àϼ³
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
receptors, serotonin Cell-surface proteins that bind serotonin and trigger intracellular changes which influence the behaviour of cells. Several types of serotonin receptors have been recognised which differ in their pharmacology, molecular biology, and mode of action.
(12 Dec 1998)
selective serotonin reuptake inhibitor <pharmacology> This is a class of drug that are used as antidepressants.
Functionally, they increase the levels of serotonin in the body. These drugs can be dangerous if they are mixed with other drugs such as other antidepressants, illicit drugs (LSD, cocaine, methamphetamine), some antihistamines (Seldane, Histmanal), some antibiotics, and calcium channel blockers.
Side effects include lethargy, confusion, flushing, sweating and muscle spasms. Overdose can cause damage to red blood cells, breathing problems and kidney damage.
Examples include: Prozac, Zoloft and Paxil.
Acronym: SSRI
(12 Jan 1998)
serotonin <biochemistry, hormone> A neurotransmitter and hormone (176 kD), found in vertebrates, invertebrates and plants. It is synthesised from the amino acid tryptophan by enterochromaffin cells in the gut and bronchi. It is metabolised to 5-HIAA in the liver and then excreted in the urine.
Serotonin is measured on a venipuncture specimen in cases of suspected carcinoid syndrome (where it will be elevated). The normal range is 101 to 283 ng/ml.
Acronym: 5-HT
(13 Nov 1997)
serotonin agents Drugs used for their effects on serotonergic systems. Among these are drugs that affect serotonin receptors, the life cycle of serotonin, and the survival of serotonergic neurons.
(12 Dec 1998)
serotonin agonists Agents that have an affinity for serotonin receptors and are able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. These compounds are used as antidepressants, anxiolytics, and in the treatment of migraine.
(12 Dec 1998)
serotonin antagonists Drugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonin agonists.
(12 Dec 1998)
serotonin-binding protein kinase <enzyme> An aspect of protein kinases EC 2.7.1.37
Registry number: EC 2.7.1.-
Synonym: sbp kinase
(26 Jun 1999)
serotonin uptake inhibitors Compounds that specifically inhibit the reuptake of serotonin in the brain. This increases the serotonin concentration in the synaptic cleft which then activates serotonin receptors to a greater extent. These agents have been used in treatment of depression, panic disorder, obsessive-compulsive behaviour, and alcoholism, as analgesics, and to treat obesity and bulimia. Many of the adrenergic uptake inhibitors also inhibit serotonin uptake; they are not included here.
(12 Dec 1998)
adaptor hypothesis A hypothesis, proposed by F.H.C. Crick, that an adaptor molecule must be present between the information-containing DNA and the protein being synthesised.
(05 Mar 2000)
altered self hypothesis The hypothesis that the T-cell receptor in MHC mediated phenomena recognises a syngeneic MHC Class I or Class II molecule after modification by a virus or certain chemicals.
See: MHC restriction.
(18 Nov 1997)
alternative hypothesis In Neyman-Pearson testing of a hypothesis, the hypothesis or family of hypotheses about the numerical value of a parameter if and only if the null hypothesis is rejected as untenable.
(05 Mar 2000)
autocrine hypothesis That tumour cells containing viral oncogenes may have encoded a growth factor, normally produced by other cell types, and thereby produce the factor autonomously, leading to uncontrolled proliferation.
(05 Mar 2000)
Avogadro's hypothesis <physics> The hypothesis that equal volumes of two different gases at the same temperature and pressure contain the same number of molecules.
(02 Jan 1998)
Bayesian hypothesis An array of surmised values of a parameter to be severally explored in the light of a current set of data, with logical symmetry being preserved among all. The merits of each hypothesis entertained are based on quantity, the prior probability. The probability of the data conditional on the hypothesis is computed as the conditional probability for each; the product of the two for each hypothesis is the joint probability, and the ratio of each joint probability to the sum of all the joint probabilities is the posterior probability for that hypothesis. Unlike the Neyman-Pearson test of hypotheses, the answer is a statement about the hypothesis, not about the sample conditional on the hypothesis. No hypothesis is preferred or prevails by default. The procedure may be applied recursively any number of times, as the data becomes available.
(05 Mar 2000)
Makeham's hypothesis A development of Gompertz' hypothesis as to the force of mortality following some mathematical law. Makeham assumed that death was the consequence of two generally coexisting causes: 1) chance; 2) a deterioration or increased inability to withstand destruction. The first of these is constant, the second is an increasing geometrical progression.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • serotonin
    ¼¼·ÎÅä´Ñ(Ç÷¾× ¼Ó¿¡ Æ÷ÇԵǴ º¹ÇվƹÎ)
  • hypothesis
    °¡¼³
  • efficient market hypothesis
    (Áõ±Ç)È¿À²Àû ½ÃÀå °¡¼³(»õ·Î¿î Á¤º¸ÀÇ ÁÖ°¡¿¡ÀÇ ¹ÝÀÀÀº µ¿½ÃÀûÀ̶õ °¡¼³)
  • hypothesis
    °¡¼³;°¡Á¤
  • nebular hypothesis(theory)
    (õ)(žç°èÀÇ)¼º¿î¼³
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 1
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 1
ÅëÇÕ°Ë»ö ¿Ï·á